TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC

Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at the 2018 Gastrointestinal Cancers Symposium.

keynote-062 trial, tactics trial, tace plus sorafenib, unresectable HCC, gastrointestinal, gastrointestinal cancers symposium